Lionco Pharm Grp Co Ltd
Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, and other applications. The company was founded in 2003 a… Read more
Lionco Pharm Grp Co Ltd (603669) - Total Assets
Latest total assets as of September 2025: CN¥1.20 Billion CNY
Based on the latest financial reports, Lionco Pharm Grp Co Ltd (603669) holds total assets worth CN¥1.20 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lionco Pharm Grp Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Lionco Pharm Grp Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lionco Pharm Grp Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Lionco Pharm Grp Co Ltd's total assets of CN¥1.20 Billion consist of 46.7% current assets and 53.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 20.2% |
| Accounts Receivable | CN¥247.89 Million | 19.8% |
| Inventory | CN¥27.88 Million | 2.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥100.90 Million | 8.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Lionco Pharm Grp Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lionco Pharm Grp Co Ltd's current assets represent 46.7% of total assets in 2024, a decrease from 56.0% in 2011.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2024, up from 19.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, unchanged from 8.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 19.8% of total assets.
Lionco Pharm Grp Co Ltd Competitors by Total Assets
Key competitors of Lionco Pharm Grp Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Lionco Pharm Grp Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Lionco Pharm Grp Co Ltd generates 0.30x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Lionco Pharm Grp Co Ltd is currently not profitable relative to its asset base.
Lionco Pharm Grp Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.11 | 5.64 | 2.79 |
| Quick Ratio | 2.80 | 4.94 | 2.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥390.28 Million | CN¥ 407.44 Million | CN¥ 1.31 Billion |
Lionco Pharm Grp Co Ltd - Advanced Valuation Insights
This section examines the relationship between Lionco Pharm Grp Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.47 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -22.7% |
| Total Assets | CN¥1.26 Billion |
| Market Capitalization | $154.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lionco Pharm Grp Co Ltd's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lionco Pharm Grp Co Ltd's assets decreased by 22.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lionco Pharm Grp Co Ltd (2011–2024)
The table below shows the annual total assets of Lionco Pharm Grp Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.26 Billion | -22.73% |
| 2023-12-31 | CN¥1.62 Billion | -12.44% |
| 2022-12-31 | CN¥1.86 Billion | -26.21% |
| 2021-12-31 | CN¥2.51 Billion | -7.43% |
| 2020-12-31 | CN¥2.72 Billion | +41.95% |
| 2019-12-31 | CN¥1.91 Billion | -7.47% |
| 2018-12-31 | CN¥2.07 Billion | +25.20% |
| 2017-12-31 | CN¥1.65 Billion | +22.89% |
| 2016-12-31 | CN¥1.34 Billion | +0.04% |
| 2015-12-31 | CN¥1.34 Billion | +139.98% |
| 2014-12-31 | CN¥559.83 Million | -3.83% |
| 2013-12-31 | CN¥582.12 Million | +59.53% |
| 2012-12-31 | CN¥364.89 Million | +49.31% |
| 2011-12-31 | CN¥244.38 Million | -- |